Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Colon Cancer
Advances in the Treatment of Metastatic Colon Cancer
The addition of new therapies based on the results of biomarker testing has substantially expanded treatment options for metastatic colorectal cancer (mCRC) in recent years, raising new questions about how to select the most appropriate therapy for a specific patient based on their biomarker testing results and how to optimally sequence these therapies. Education is needed to help guide clinicians on appropriate biomarker testing for patients with mCRC and how the results of these tests can aid in treatment decision-making in this rapidly evolving landscape. Optimal treatment strategies can maximize benefits while minimizing harms, giving patients with mCRC the best quality and quantity of life possible.
Target Audience
This educational program is designed to meet the educational needs of physicians/oncologists, nurse practitioners, nurses, physician assistants, pharmacists, and other health care professionals who manage patients with cancer.
Learning Objectives
Following this activity, participants should be able to:
- Describe considerations for biomarker testing in patients with metastatic colorectal cancer (mCRC), including interpretation of results and their impact on treatment selection.
- Compare and contrast recent and emerging targeted therapy options for mCRC and how these new therapies may be incorporated into a treatment plan.
- Explain results of recent clinical trials of systemic therapies for patients with mCRC.
Dara L. Aisner, MD, PhD
University of Colorado Cancer Center
Wells A. Messersmith, MD
University of Colorado Cancer Center
NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics).
Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.
Definitions
NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.
NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship.
Faculty Disclaimers
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.
Faculty Disclosures
The faculty listed below discloses the following relevant financial relationships:
Dara L. Aisner, MD, PhD
Blueprint Medicines: Honoraria
Genentech, Inc.: Grant/Research Support
Wells A. Messersmith, MD
Alexo Therapeutics, Inc.: Grant/Research Support
D3 Pharma: Grant/Research Support
Five Prime: Grant/Research Support
Genentech, Inc.: Grant/Research Support
Gilead Sciences, Inc.: Other Financial Benefit
Immunomedics, Inc.: Grant/Research Support
Incyte Corporation: Grant/Research Support
Millennium Pharmaceuticals, Inc.: Grant/Research Support
OncoMed Pharmaceuticals: Grant/Research Support
Pfizer Inc.: Grant/Research Support
Roche Laboratories, Inc.: Grant/Research Support
Tanabe Research Labs USA Inc.: Grant/Research Support
NCCN Staff Disclosures
The NCCN Activity Planning staff listed below discloses no relevant financial relationships:
Mike Abrams; Melissa Esplen; Mark A. Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Lisa Perfidio, MS; Shannon Ryan, CMP; Kathy Ann Smith, CHCP; Sarah Weinstein
The NCCN Clinical staff listed below discloses no relevant financial relationships:
Lisa Gurski, PhD
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
NCCN designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
NCCN designates this educational activity for a maximum of 1.0 contact hour.
Pharmacists
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit. UAN: JA4008196-0000-21-086-H01-P
Physician Assistants
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until May 21, 2022. PAs should only claim credit commensurate with the extent of their participation.
Case Managers
This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board certified case managers. The course is approved for 1.0 CE contact hour. Activity Code: I00046207; Approval #: 210001575
Available Credit
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 CCM clock hours
- 1.00 Participation
Price
Required Hardware/software
To complete this activity, users will need:
- A device with an Internet connection and sound playback capability
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
- Internet Explorer is no longer supported
- Adobe Reader or other PDF reader software for certificate viewing/printing